Detalhe da pesquisa
1.
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Br J Haematol
; 204(5): 1825-1829, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286472
2.
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.
Hematol Oncol
; 40(4): 695-703, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488778
3.
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Biol Blood Marrow Transplant
; 26(12): 2217-2222, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818553
4.
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
Oncologist
; 25(8): 689-695, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32319706
5.
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Blood
; 131(2): 182-190, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074501
6.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Blood
; 130(10): 1198-1204, 2017 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684537
7.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Blood
; 129(26): 3419-3427, 2017 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424162
8.
Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.
Am J Hematol
; 94(7): 786-793, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31006875
9.
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Blood
; 128(20): 2415-2422, 2016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27702799
10.
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Am J Hematol
; 93(2): 187-194, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29080258
11.
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Am J Hematol
; 92(10): 1004-1010, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28614905
12.
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Am J Hematol
; 92(5): 448-453, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211162
13.
Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
J Immunol
; 192(4): 1620-9, 2014 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24431228
14.
Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B.
Br J Haematol
; 191(2): e41-e43, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33460052
15.
Elevated soluble IL-2Rα, IL-8, and MIP-1ß levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.
Am J Hematol
; 89(12): E223-7, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25164110
16.
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.
Cancers (Basel)
; 15(2)2023 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36672426
17.
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
Blood Adv
; 6(18): 5429-5435, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737873
18.
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
J Clin Oncol
; 39(15): 1641-1649, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33529046
19.
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Am J Hematol
; 85(5): 320-4, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20229590
20.
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study.
Am J Hematol
; 84(12): 795-8, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19894247